MedTrace Logo

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A

NCT06328712 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-12-23

No results posted yet for this study

Summary

An Open, Dose-escalation, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients with Charcot-Marie-Tooth Disease type 1A (CMT1A)

Conditions

  • Charcot-Marie-Tooth Disease Type 1A

Interventions

DRUG

EN001

* Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals. * Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.

Sponsors & Collaborators

  • ENCell

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06328712 on ClinicalTrials.gov